SUNNYVALE, Calif., May 30 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. announced today that Richard A. Miller, M.D., president and chief executive officer, will make a company presentation at the 2007 Friedman Billings Ramsey Growth Conference on Thursday, May 31st, at 9:00 a.m. EDT at The Grand Hyatt in New York City.
To access the live audio broadcast or the subsequent archived recording log on to http://ir.pharmacyclics.com. The archived version of the webcast will be available on the company's website for one month.
About Pharmacyclics
Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin(R) (motexafin gadolinium) Injection, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin, either as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. A New Drug Application for use of Xcytrin in combination with whole brain radiation therapy for treatment of brain metastases from non-small cell lung cancer was filed with the Food and Drug Administration in April 2007. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. In addition, more information about advocacy on behalf of Xcytrin can be found at http://www.yourcanceryourchoice.com. Pharmacyclics(R), Xcytrin(R) and the "pentadentate" logo(R) are registered trademarks of Pharmacyclics, Inc.
Pharmacyclics, Inc.CONTACT: Leiv Lea of Pharmacyclics, Inc., +1-408-774-0330, or CarolynBumgardner Wang of WeissComm Partners, +1-415-946-1065
